In addition, the melanoma mouse model demonstrated that mobilization of cDC1 alone is insufficient in generating anti-tumor T cell response in tumors and that addition of the TLR3 agonist, which activates type I IFN signaling in cDC1, is necessary to enhance response to anti-PD-1 Ab (17). Here, TLR3 is linked to neoplasm.